Dear Editor,
As of June 12, 2015, the World Health Organization had been notified of 1289 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection globally, including at least 455 related deaths (case-fatality rate of 35%) (http://www.who.int/csr/don/12-june-2015-mers-korea/en/). On May 20, a 68-year-old man returning to the Republic of Korea from a trip to Saudi Arabia was diagnosed with MERS-CoV infection, and since then, the virus has spread, resulting in a cluster of 145 MERS-CoV cases, including 14 deaths, in South Korea and China (http://www.who.int/csr/disease/coronavirus_infections/en/), bringing the total number of countries reporting MERS-CoV infection to 25. This patient became the one of the most active “MERS super-spreader”, while the MERS super-spreader in Abu Dhabi was linked to 28 confirmed MERS cases (http://www.recombinomics.com/News/04291401/UAE_MERS_Superspreader_28.html).
Most of these cases in this cluster represent medical staff, family and other caregivers, or those close to the original patient before he was diagnosed with MERS-CoV infection and isolated. Therefore, an understandable sense of panic has arisen among those who have had contact with the newly diagnosed cases. This is yet another alarm sounding the necessity for the rapid development of therapeutic and prophylactic agents to treat MERS patients and protect high-risk populations from MERS-CoV until an effective and safe vaccine is available.Citation1,Citation2
Based on our previous experience in developing viral fusion inhibitors against HIVCitation3 and SARS-CoV,Citation4 we designed and synthesized a peptide (HR2P) derived from the HR2 domain in the S2 subunit of the spike (S) protein of the MERS-CoV EMC/2012 strain. We found that HR2P could bind with the HR1 domain to form a stable six-helix bundle and thus inhibit viral fusion core formation and S protein-mediated cell-cell fusion. HR2P was demonstrated to potently inhibit infection by both pseudotyped and live MERS-CoV in different cell lines.Citation5 We then modified the HR2P peptide by introducing Glu (E) and Lys (K) residues at the i to i+4 or i to i+3 arrangements. We found that one of these HR2P analogous peptides, HR2P-M2, exhibited significantly improved stability, solubility and antiviral activity.Citation5
Interestingly, the HR2P-M2 peptide could potently inhibit infection by pseudoviruses expressing MERS-CoV S protein with or without mutation in the HR1 region, suggesting that it could be effective against most currently available MERS-CoV mutants. We further demonstrated that the HR2P-M2 peptide administered via the intranasal route could protect Ad5-hDPP4-transduced miceCitation6 from challenge by MERS-CoV strains with or without mutations in the HR1 region, indicating that this peptide could be used as a nasal spray to protect high-risk populations, including healthcare workers, MERS patients’ family members, and those having close contacts with the patients, from MERS-CoV infection.Citation7 Intranasal application of the peptide to MERS-CoV-infected patients may suppress viral replication in epithelial cells of the respiratory tract and thus reduce the release of virions, thereby preventing the spreading of MERS-CoV to other people.
Furthermore, we and other groups have identified monoclonal antibodies (mAbs) targeting neutralizing epitopes in the receptor-binding domain of the S1 subunit of MERS-CoV S protein. These mAbs, including m336,Citation8 MERS-4,Citation9 3B11,Citation10 and Mersmab1,Citation11 have shown potent neutralizing activity against MERS-CoV. The human mAb m336, which was derived from a very large naive antibody library, belongs to the IgG1 subclass, with high avidity (99 pM) and neutralizing activity against pseudotyped and authentic MERS-CoV (the half maximal inhibitory concentration of 0.033 and 0.47 nM, respectively).Citation12 More interestingly, the m336 mAb is a germline-like antibody with only one mutation in the heavy chain and five in the light chain. As such, it is safe for humans, highly expressible, and highly soluble. In vivo studies have shown that this mAb is very effective in protecting MERS-CoV-susceptible animals from viral challenge (unpublished data), suggesting that the m336m mAb is a very promising drug candidate for the urgent treatment of MERS-CoV-infected patients.Citation12
We have also performed in vitro studies demonstrating that the combination of HR2P-M2 peptide with m336 mAb exhibited a strong synergistic effect against MERS-CoV infection (unpublished data). This observation suggests that intranasal administration of HR2P-M2 peptide combined with intravenous administration of m336 mAb may be a powerful strategy for treatment of MERS patients.
Laboratory-produced mAbs m102.4, a human mAb against Hendra virus and Nipah virus, and Zmapp, comprising three chimeric mAbs against Ebola virus, have shown good in vivo efficacy in animal modelsCitation13,Citation14 and have been successfully used in clinics to treat patients infected by Hendra virus or Nipah virusCitation13 and Ebola virus,Citation15 respectively. Therefore, it can be plausibly suggested that m336 mAb and HR2P-M2 peptide, both of which have demonstrated excellent in vivo efficacy in animal models, may also have high potential for clinical application in both urgent and prophylactic treatment of MERS patients.
We thank Drs. Rongguang Zhang, Yun Zhu, and Sheng Ye at the Institute of Biophysics, Chinese Academy of Sciences, Beijing, China; Drs. Kwok-Yung Yuen, Kwok-Hung Chan, Bo-Jian Zheng, Jasper Fuk-Woo Chan, and Candy C. Y. Lau at the University of Hong Kong, Hong Kong, China; Drs. Stanley Perlman, Rudragouda Channappanavar, and David K. Meyerholz at the University of Iowa, Iowa City, Iowa, USA; Drs. Dimiter S Dimitrov, Ponraj Prabakaran, Tina W Ju, Yang Feng, and Yanping Wang at the National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA; Drs. Lanying Du, Cuiqing Ma, and Lili Wang at the New York Blood Center, New York, New York, USA; and Drs. Qi Liu, Fei Yu, Yuan Li, and Qian Wang at Fudan University, Shanghai, China, for their contribution to the original studies cited in this letter.
- Lu L, Liu Q, Du L, Jiang S.Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect 2013;15: 625–629.
- Hotez PJ, Bottazzi ME, Tseng CT et al.Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect 2014;16: 529–531.
- Jiang S, Lin K, Strick N, Neurath AR.HIV-1 inhibition by a peptide. Nature 1993;365: 113.
- Liu S, Xiao G, Chen Y et al.Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004;363: 938–947.
- Lu L, Liu Q, Zhu Y et al.Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 2014;5: 3067.
- Zhao J, Li K, Wohlford-Lenane C et al.Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014;111: 4970–4975.
- Channappanavar R, Lu L, Xia S et al.Protective effect of intranasal regimens containing peptidic MERS-CoV fusion inhibitor against MERS-CoV infection. J Infect Dis 2015;doi: 10.1093/infdis/jiV325.
- Ying T, Du L, Ju TW et al.Exceptionally potent neutralization of MERS-CoV by human monoclonal antibodies. J Virol 2014;88: 7796–7805.
- Jiang L, Wang N, Zuo T et al.Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014;6: 234ra59.
- Tang XC, Agnihothram SS, Jiao Y et al.Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA 2014;111: E2018–E2026..
- Du L, Zhao G, Yang Y et al.A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in MERS-CoV spike protein. J Virol 2014;88: 7045–7053.
- Ying T, Li H, Lu L, Dimitrov DS, Jiang S.Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microbes Infect 2015;17: 142–148.
- Geisbert TW, Mire CE, Geisbert JB et al.Therapeutic Treatment of Nipah Virus Infection in Nonhuman Primates with a Neutralizing Human Monoclonal Antibody. Sci Transl Med 2014;6: 242ra82.
- Geisbert TW.Medical research: Ebola therapy protects severely ill monkeys. Nature 2014;514: 41–43.
- Lyon GM, Mehta AK, Varkey JB et al.Clinical Care of Two Patients with Ebola Virus Disease in the United States. N Engl J Med 2014;371: 2402–2409.